Transcript Document

Company Profile
 A fast growing, fully integrated, research oriented pharmaceutical company
with a Global presence
 Revenues in FY 2013-14 `7277 Mn (US $ 121 Mn)
 Domestic business contributes 64% and international business contributes
36% of the revenues
 Formulation business contributes 93% and API business contributes 7% of
revenues
 Workforce of over 4500
- 200 R&D scientists
- 2300 field staff
Our Infrastructure
 Corporate Office at Santacruz (E), Mumbai
 8 Manufacturing Facilities
- 5 FDFs
- 3 APIs
 R&D Centre at Navi Mumbai
 29 C&Fs
Mfg. Facilities for FDFs
LOCATION
DOSAGE FORM
APPROVALS
TABLETS, CREAMS &
OINTMENTS
US-FDA, EU-GMP,
TGA Australia,
MCC South Africa,
ANVISA - Brazil
GOA II
STERILE PRODUCTS
US-FDA, EU-GMP,
MCC South Africa,
TGA Australia
GOA III
TABLETS
US-FDA, EU-GMP,
TGA Australia,
WALUJ
TABLETS
Emerging Markets
BADDI
TABLETS, LIQUID
ORALS &
TOOTHPASTES
EU–GMP and
Emerging Markets
GOA I
API facilities
 Multi-ton : Patalganga (USFDA , TGA Australia
approved)
- Reactor Capacity: 500 to 5000 L
 Kilo Scale: Navi Mumbai (USFDA , TGA Australia
approved)
- Reaction Systems: 16 to 500 L
- Total Reactor Volume: 1 cubic meters
- Temperatures range: -55 to + 150 celsius
 Intermediates : Rabale
- Reactor Capacity: 500 to 3000 L
- Total Reactor Volume: 50 cubic meters
Research & Development
 US $ 10 Mn Investment in R&D set-up
 Spread over an area of 150,000 square feet and
employs over 200 scientists and technical
personnel
 58 Patents filed
- 38 for APIs
- 20 for FDFs
Business Model
• Branded Generics
- 8 Marketing Divisions
- 18 Therapeutic Segments
- 150 Brands
• APIs
INTERNATIONAL
BUSINESS
(Covers 80 countries)
• Regulated Markets
- Generic Business
- CRAMS
- Alliances
• Emerging Markets
- Branded Generics
- Through Distributors
- Alliance
Indian Business
8 MARKETING DIVISIONS
INDOCO
GPs, CPs, Gynaec, Pediatrician
SPADE
GPs, CPs, Pediatrician, ENTs, Otologicals
WARREN
Dental
EXCEL
Opthalmic
SPERA
GPs, Gynaec, Pediatrician
ETERNA
CPs, Orthos, Gastro
INDOCO CND
Lifestyle / Cardio & Diabetology
INSTITUTION
Caters to Hospital & Government Supplies
 Ranked 27th by CMARC in Rx Ranking
 Ranked 28th by AWACS in SSA Audit (Sept’14)
Growth Drivers (Domestic Business)
 Growing middle class population, increasing income levels, rapid
urbanization, demand for quality healthcare services & changing lifestyle
 Focus on chronic segment
 Penetration in Northern and Eastern Regions
 New Products introductions (around 20 products every year)
 Growth above Industry Average
International Business
Regulated Markets
Emerging Markets
(85% of
(15% of
Formulation
Formulation
Export Business)
Export Business)
Revenue of
Rs. 2005 Mn in FY14
(US $ 33 Mn)
Revenue of
Rs. 307 Mn in FY14
(US $ 5 Mn)
Revenue contribution
UK 48%, USA 23 %,
SA 12%, Germany 8%)
CRAMS,
Dossier Out-Licensing,
Out-Licensing of MAs
Actavis (Watson) Partnership
Revenue contribution
Africa 8%, Asia 2%,
Latam 2%
Promotion of Branded
Generics through
Distributors
Aspen Partnership
Growth Drivers (International Business)
 Strong Partnership with Watson Pharmaceuticals Inc., USA
 Multi-product, Multi-territory alliance with Aspen Pharmacare, SA
 Own filing of ANDAs and Dossiers
 NDDS and new technology platforms
Segment wise Break-up and Contribution
2008-09
2003-04
7%
2%
2013-14
7%
5%
27%
32%
68%
91%
61%
Profit & Loss A/C – Percentage to Net Sales
Quarter Ended
Particulars
INCOME
Net Sales / Income from
Operations
Add: Other Operating Income
Total Income from
Operations
Add: Other Income
Total Income
EXPENDITURE
Material Cost
Employees Benefit Expenses
Research & Development
Expenses
Other Expenses
Finance Cost
Depreciation and Amortisation
Expenses
Misc. Expenditure Written Off.
30.09.14
(Unaudited)
% to
Sales
(` In Lacs)
Half Year Ended
30.09.13
(Unaudited)
% to
Sales
30.09.14
(Unaudited)
% to
Sales
30.09.13
(Unaudited)
Year Ended
31.03.14
% to
(Audited)
Sales
22642
19505
42437
34310
201
726
269
1318
71737
1034
22843
20231
42706
35628
72771
56
22899
46
20277
118
42824
62
35690
175
72946
% to
Sales
7971
3596
35.2
15.9
7576
3338
38.8
17.1
15228
6970
35.9
16.4
13545
6221
39.5
18.1
26916
12905
37.5
18.0
489
2.2
384
2.0
918
2.2
658
1.9
1443
2.0
5924
268
26.2
1.2
5635
527
28.9
2.7
11070
541
26.1
1.3
9468
1149
27.6
3.3
19500
1880
27.2
2.6
1315
5.8
772
4.0
2262
5.3
1505
4.4
3091
4.3
-
-
-
-
-
1
Total Expenses
PBT
Tax Expenses
PAT
EBIDTA (w/o R&D)
19563
3336
1095
2241
5352
9.9
23.6
18232
2045
441
1604
3682
EBIDTA (with R&D)
4863
21.5
Operating Profit
3769
16.7
14.7
-
-
8.2
18.9
3298
16.9
8520
20.1
5736
16.7
12008
16.7
2383
12.2
6635
15.6
3740
10.9
8479
11.8
10.5
10.0
22.2
32546
3144
622
2522
6394
7.4
18.6
65735
7211
1421
5790
13451
-
36989
5835
1590
4245
9438
13.7
9.2
10.1
8.1
18.8